GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting October 6, 2022
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies September 12, 2022
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September September 8, 2022
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update August 11, 2022
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress June 10, 2022
